Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.38% | -12.44% | -10.41% | -13.37% | -15.51% |
| Total Depreciation and Amortization | 50.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.74% | 1.32% | -7.99% | -31.97% | 69.91% |
| Change in Net Operating Assets | 176.90% | 22.63% | -204.36% | 15,651.61% | -98.03% |
| Cash from Operations | 37.61% | -7.68% | -63.30% | 3.53% | -20.61% |
| Capital Expenditure | 100.00% | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.14% | 0.00% | -55.56% | -- | -- |
| Issuance of Common Stock | -41.01% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | 91.89% | -85.00% | 89.19% | 39.54% | 41.94% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -40.88% | 27,341.18% | -100.05% | 20,567.65% | 41.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.56% | 19.99% | -179.47% | 295.60% | -18.61% |